By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mateon Therapeutics, Inc. 

701 Gateway Boulevard
Suite 210
South San Francisco  California  94070  U.S.A.
Phone: 650-735-7000 Fax: 650-735-7001


Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.

At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.

Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.

Key Statistics

Ownership: Public

Web Site: Mateon Therapeutics
Symbol: MATN

Company News
Mateon Therapeutics (MATN) Announces Results From Second Interim Analysis Of CA4P Phase II/III FOCUS Study In Platinum-Resistant Ovarian Cancer 8/16/2017 7:07:54 AM
Mateon Therapeutics (MATN) Provides Corporate Update and Reports Second Quarter 2017 Financial Results 8/3/2017 1:36:31 PM
Mateon Therapeutics (MATN) Completes Enrollment In Phase II Portion Of FOCUS Study Of CA4P For Platinum-Resistant Ovarian Cancer 8/1/2017 11:56:01 AM
Mateon Therapeutics (MATN) Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML 7/31/2017 11:34:36 AM
Mateon Therapeutics (MATN) Announces New Interim Preclinical Data On CA4P In Combination With Checkpoint Inhibitors 6/28/2017 7:42:41 AM
Mateon Therapeutics (MATN) Provides Update On Its Clinical Trial Programs And Milestones 6/12/2017 11:48:12 AM
Mateon Therapeutics (MATN) Receives FDA Fast Track Designation For Oxi4503 In Patients With Acute Myeloid Leukemia 6/7/2017 8:15:16 AM
Mateon Therapeutics (MATN) Provides Corporate Update And Reports First Quarter 2017 Financial Results 5/9/2017 10:21:02 AM
Mateon Therapeutics (MATN) Announces Initiation Of Investigator-Sponsored Phase I Study Of CA4P In Combination With Everolimus In Neuroendocrine Tumors 4/20/2017 9:00:55 AM
Mateon Therapeutics (MATN) Announces Encouraging Results From First Interim Analysis Of Phase II/III FOCUS Study In Platinum-Resistant Ovarian Cancer 4/18/2017 10:42:47 AM